Radius Health (RDUS) Reports Prelim. FY18 Product Revenue Guidance for TYMLOS; Maintains FY19 TYMLOS Sales Guidance

Radius Health, Inc. (NASDAQ: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million. Radius closed 2018 with a $235 million cash, cash equivalents and investments balance achieving its year-end guidance to be above $220 million.

“I am very pleased with the continued strong growth trajectory of TYMLOS which reached an exit 40% share in new patients in its first full-year in the U.S. market. 2019 will be a pivotal year for us as we move closer to our goal of U.S. anabolic market leadership and expect to advance our late-stage clinical pipeline of two innovative Phase 3 products, elacestrant and abaloparatide-patch, both with blockbuster potential,” said Jesper Hoeiland, President and Chief Executive Officer of Radius.

Elacestrant’s Phase 3 EMERALD study was initiated in December 2018. It is the first phase 3 study to prospectively evaluate treatment benefit for second- and third-line breast cancer patients following cyclin-dependent kinase (CDK) 4/6 inhibitor therapy as well as prospectively compare outcomes in patients whose tumors harbor estrogen receptor 1 gene (ESR1) mutations.

In 2018, TYMLOS captured on average 20% of the U.S. anabolic osteoporosis market and exited the year with a 27% total U.S. anabolic market share and 40% share of new anabolic patient starts in December. TYMLOS is currently the only promoted anabolic drug in the U.S. market and is consistently increasing its prescriber base.

A 5.9% price increase for TYMLOS took effect on January 1, 2019.

Radius maintains its financial guidance for 2019 and expects full-year TYMLOS U.S. net sales to be between $155 to $175 million and its year-end cash, cash equivalents and investments balance to exceed $100 million.

The Company will present further details at the 37^th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 1:30 pm PST at the Westin St. Francis Hotel in San Francisco, California. A live webcast of the presentation will be available by visiting the Investors section of Radius’ website at https://ir.radiuspharm.com/events-and-presentations. A replay of the webcast will be archived on Radius’ website for 90 days following the presentation.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Manhattan Associates, Inc. (MANH) Tops Q1 EPS by 16c; offers guidance
• Bunge Limited (BG) and Viterra Issue Statement on Canadian Competition Bureau Report